Abstract: The invention relates to compounds of Formula (I): and related aspects.

Abstract: The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical composition comprising gaboxadol and one or more anti-inflammatory compounds. The present invention further relates to a method of treating a disease wherein one or more inflammatory markers are increased, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that enhances GABAA-ergic neurotransmission.

Abstract: A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.

Abstract: DNA encoding a novel human GABAB receptor subunit, HG20, as well as the protein encoded by the DNA, is provided. Also provided is DNA encoding a novel murine GABAB receptor subunit, GABABR1a, as well as the protein encoded by the DNA. Heterodimers of HG20 protein and GABABR1a protein that form a functional GABAB receptor are disclosed. Methods of identifying agonists and antagonists of the GABAB receptor are also provided.